New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
07:33 EDTOPXA, MKGAYOpexa Therapeutics, Merck Serono enter into license agreement for Tcelna
Opexa Therapeutics (OPXA) announced the execution of an agreement with Merck Serono, a division of Merck (MKGAY) for the development and commercialization of Tcelna, a potential first-in-class personalized T-cell therapy for patients suffering from multiple sclerosis. Tcelna is being developed by Opexa and currently is in a Phase IIb clinical trial in patients with Secondary Progressive MS. Potential payments to Opexa from the option and license agreement could total $225M based upon the successful development and commercialization of Tcelna for MS. Under the terms of the agreement, Opexa will receive an upfront payment of $5M for granting an option to Merck Serono for the exclusive license of the Tcelna program for the treatment of MS. The option may be exercised prior to or upon completion of Opexa’s ongoing Phase IIb clinical trial in patients with SPMS. Upon exercising this licensing option, Merck Serono would pay an upfront license fee of either $25M or $15M, and in return receive worldwide development and commercial rights to Tcelna in MS, excluding Japan. Additional financial considerations of the agreement include development and commercial milestone payments to Opexa of up to $195M and a tiered royalty rate from the high single digits to the mid-teens based on net sales payable to Opexa.
News For OPXA;MKGAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
09:06 EDTOPXAOpexa Therapeutics announces allowance of 98th T-cell patent
Subscribe for More Information
September 22, 2014
16:18 EDTMKGAYOn The Fly: Closing Wrap
Subscribe for More Information
12:16 EDTMKGAYOn The Fly: Midday Wrap
Subscribe for More Information
09:41 EDTMKGAYMerck KGaA expects moderate downgrade due to purchase price for Sigma-Aldrich
Subscribe for More Information
09:31 EDTMKGAYMerck KGaA says dividend increase possible following Sigma-Aldrich acquisition
Subscribe for More Information
09:28 EDTMKGAYMerck KGaA says too early to know split of retained, reinvested cost savings
Subscribe for More Information
09:23 EDTMKGAYMerck KGaA: Sigma-Aldrich acquisition is not a tax inversion deal
Subscribe for More Information
09:19 EDTMKGAYMerck KGaA: Sigma-Aldrich deal is quantum leap for life sciences business
Subscribe for More Information
09:15 EDTMKGAYOn The Fly: Pre-market Movers
HIGHER: Sigma-Aldrich (SIAL), up 34% after Merck KGaA (MKGAY) to acquire the company for $17B... Viasystems (VIAS), up 44% after TTM Technologies (TTMI) acquires the company for $16.46 per share in cash and stock. TTM is up 15.5% after the deal... Clorox (CLX), up 5.4% after the New York Post said the company turned down offer to sell or merge with rival... EMC (EMC), up 2.5% after The Wall Street Journal said the company is considering options that could include merging with a rival and held on-and-off merger talks with Hewlett-Packard (HPQ) for almost a year, though the Journal added that those talks recently ended... Epiq Systems (EPIQ), up 9.9% after P2 Capital confirms 16.9% stake in Epiq and that the company turned down the shareholders' $20 per share takeover offer... Dresser-Rand (DRC), up 2.7% after the company sells to Siemens (SIEGY) for $83 per share or $7.6B... TAT Technologies (TATT), up 6.6% after a division of the company signed a maintenance agreement with Republic Airways (RJET). LOWER: Yahoo (YHOO), down 2.1% after stock was downgraded at Bank of America Merrill Lynch and at Bernstein... InvenSense (INVN), down 2.9% after downgraded at RW Baird... Threshold Pharmaceuticals (THLD), down 5.6% after TH-302 Phase 3 trial events to occur later than expected.
06:52 EDTMKGAYSigma-Aldrich volatility expected to move on Merck KGaA acquiring for $17B
Subscribe for More Information
06:06 EDTMKGAYMerck KGaA says transaction approved by Sigma-Aldrich's board of directors
The transaction has been unanimously approved by Sigma - Aldrich’s Board of Directors. A merger agreement will be presented to Sigma - Aldrich shareholders for approval at a special meeting of shareholders. The transactio n has the full support of Merck KGaA, Darmstadt, Germany ’s Executive Board and E. Merck KG including its Board of Partners, and a Merck KGaA, Darmstadt, Germany,shareholder vote will not be required. Closing is expected in mid- year 2015, subject to regulatory approvals and other customary closing conditions. Guggenheim Securities and J.P. Morgan are acting as financial advisers to Merck KGaA, Darmstadt, Germany . Skadden , Arps, Slate, Meagher & Flom LLP is acting as legal adviser to Merck KGaA, Darmstadt, Germany . Morgan Stanley & Co. LLC is acting as financial adviser to Sigma -Aldrich and Sidley Austin LLP is acting as legal adviser.
06:01 EDTMKGAYMerck KGaA to acquire Sigma-Aldrich for $17B
Subscribe for More Information
06:00 EDTMKGAYMerck KGaA to acquire Sigma-Aldrich for $17B
Subscribe for More Information
September 18, 2014
11:23 EDTOPXAOpexa Therapeutics mentioned positively by Seeking Alpha contributor
Subscribe for More Information
06:21 EDTMKGAYMerck KGaA names Stefan Oschmann as deputy CEO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use